Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Kavanagh, John J ^a   Levenback, Charles F ^a   Ramirez, Pedro T ^a   Wolf, Judith L ^a   Moore, Carla L ^a   Jones, Marsha R ^b   Meng, Lisa ^b   Brown, Gail L ^b   Bast, Robert C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Telik Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CANFOSFAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTATHIONE; MACROGOL DERIVATIVE; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSURIA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUSHING; GINGIVITIS; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE PAIN; LEUKOCYTOSIS; LEUKOPENIA; LIMB PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; SURVIVAL; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 77949434537     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-9     Document Type: Article

References (33)

1. Cancer Statistics, 2009. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun, CA: A Cancer Journal for Clinicians 2009 59 4 225 49 10.3322/caac.20006 19474385
2. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. RE Bristow RS Tomacruz DK Armstrong EL Trimble FJ Montz, J Clin Oncol 2002 20 5 1248 59 10.1200/JCO.20.5.1248 11870167
3. -2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). A Du Bois M Quinn T Thigpen, et al. Ann Oncol 2005 16 Suppl 8 viii12 10.1093/annonc/mdi961 16239238
4. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. R Agarwal SB Kaye, Nat Rev Cancer 2003 3 7 502 16 10.1038/nrc1123 12835670 (Pubitemid 37328838)
5. Design Issues in Clinical Trials of Ovarian Carcinoma. T Thigpen, FDA and the American Society of Clinical Oncology (ASCO), with co-sponsorship by the American Association for Cancer Research (AACR), public workshop on endpoints for ovarian cancer 2006 http://www.fda.gov/downloads/AboutFDA/CentersOffices/ CDER/ucm120669.pdf
6. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. AN Gordon M Tonda S Sun W Rackoff, Gynecol Oncol 2004 95 1 1 8 10.1016/j.ygyno.2004.07.011 15385103 (Pubitemid 39286270)
7. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. AN Gordon JT Fleagle D Guthrie DE Parkin ME Gore AJ Lacave, J Clin Oncol 2001 19 14 3312 22 11454878 (Pubitemid 32642183)
8. Glutathione-S-transferase activates novel alkylating agents. MH Lyttle A Satyam MD Hocker, et al. J Med Chem 1994 37 10 1501 7 10.1021/jm00036a016 8182709
9. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. A Satyam MD Hocker KA Kane-Maguire AS Morgan HO Villar MH Lyttle, J Med Chem 1996 39 8 1736 47 10.1021/jm950005k 8648613 (Pubitemid 26124245)
10. Glutathione S-transferases as emerging therapeutic targets. L Gate KD Tew, Expert Opin Ther Targets 2001 5 4 477 89 10.1517/14728222.5.4.477 12540261
11. Comparison of glutathione S-transferase levels in predicting the efficacy of a novel alkylating agent. JA Montali JB Wheatley DE Schmidt Jr, Cell Pharmacol 1995 2 241 7
12. Expression of anionic glutathione- S-transferase and P-glycoprotein genes in human tissues and tumors. JA Moscow CR Fairchild MJ Madden, et al. Cancer Res 1989 49 6 1422 8 2466554
13. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. KD Tew A Monks L Barone, et al. Mol Pharmacol 1996 50 1 149 59 8700107 (Pubitemid 26250086)
14. TLK286-induced activation of JNK-dependent apoptotic signaling pathway. F Meng GL Brown JG Keck, et al. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 29-November 2, 2001; Miami Beach 67 Abstract #326
15. TLK286-induced activation of the stress response apoptotic signaling pathway. F Meng S Kim GL Brown, et al. Proceedings of the Annual Meeting of the American Association for Cancer Research; April 6-10, 2002; San Francisco, California 963 Abstract #4772
16. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. AS Morgan PE Sanderson RF Borch, et al. Cancer Res 1998 58 12 2568 75 9635580
17. Cellular response to a glutathione S-transferase P1-1 activated prodrug. LA Rosario ML O'Brien CJ Henderson CR Wolf KD Tew, Mol Pharmacol 2000 58 1 167 74 10860939
18. Efficacy of a glutathione S-transferase p-activated prodrug in platinum-resistant ovarian cancer cells. DM Townsend H Shen AL Staros L Gate KD Tew, Mol Cancer Ther 2002 1 12 1089 95 12481432
19. Synergistic effect of TELCYTA (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells. H Xu S-Y Namgoong E Roth, et al. Proceedings of the American Association for Cancer Research; July 11-14, 2003; Washington DC 462 Abstract 2008
20. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. JJ Kavanagh DM Gershenson H Choi, et al. Int J Gynecol Cancer 2005 15 4 593 600 10.1111/j.1525-1438.2005.00114.x 16014111 (Pubitemid 41022895)
21. New guidelines to evaluate the response to treatment in solid tumors. P Therasse SG Arbuck EA Eisenhauer, et al. J Natl Cancer Inst 2000 92 3 205 16 10.1093/jnci/92.3.205 10655437
22. Transfection of glutathione S-transferase (GST)-p antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. N Ban Y Takahashi T Takayama, et al. Cancer Res 1996 56 15 3577 82 8758929 (Pubitemid 26251655)
23. Phase 1-2a study of TLK286 (Telcyta, a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (>/= 3rd line) ovarian cancer. J Kavanagh A Kudelka L Lewis, et al. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 17-21, 2003; Boston, MA 222 Abstract C155
24. Common Toxicity Criteria (CTC). NCI National Cancer Institute, DCTD, NCI, NIH, DHHS 1999
25. Nonparametric estimation from incomplete observations. EL Kaplan P Meier, J Am Stat Assoc 1958 53 282 457 81 10.2307/2281868
26. Epithelial Ovarian Cancer. RF Ozols SC Rubin G Thomas S Robboy, Principles and Practice of Gynecologic Oncology Philadelphia: Lippincott-Raven Publishers, Hoskins WJ, Perez CA, Young RC, 2 1997 919 86
27. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer. J Kavanagh A Kudelka D Spriggs, et al. Proceedings of the Biennial Meeting of the International Gynecologic Cancer Society; October 20-24, 2002; Seoul, Korea 530 Abstract OV034
28. Activity of TER286 against human tumor colony-forming units. E Izbicka R Lawrence C Cerna DD Von Hoff PE Sanderson, Anticancer Drugs 1997 8 4 345 8 10.1097/00001813-199704000-00006 9180387 (Pubitemid 27204952)
29. TLK286, a novel glutathione analog prodrug, induces resensitization to carboplatin in human ovarian cancer, OVCAR3, platinum resistant cells. Z Wang JG Keck GL Brown, et al. Proceedings of the American Association for Cancer Research; April 16-20, 2005; Anaheim, CA 351 2 Abstract 1500
30. Enhanced antitumor activity of TLK286 in combination with oxaliplatin, carboplatin, doxorubicin, paclitaxel and docetaxel in human colorectal, ovarian and breast cancer cell lines. H Xu E Grossman S-Y Namgoong, et al. Proceedings of the American Association for Cancer Research; April 5-9, 2003; Toronto, Canada 390 1 Abstract 1722
31. Randomized Phase 3 Study of Canfosfamide (C, TLK286) plus Pegylated Liposomal Doxorubicin (PLD) vs PLD as Second-line Therapy in Platinum (P) Refractory or Resistant Ovarian Cancer (OC). I Vergote N Finkler J Hall, et al. Proceedings of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL 289s Abstract 5552
32. Phase 3 Randomized Study of Canfosfamide (Telcyta, TLK286) versus Pegylated Liposomal Doxorubicin or Topotecan as Third-Line Therapy in Patients with Platinum Refractory or Resistant Ovarian Cancer. I Vergote N Finkler J del Campo, et al. Eur J Cancer 2009 45 2324 32 10.1016/j.ejca.2009.05.016 19515553
33. Phase 3 study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC). P Rose R Edwards N Finkler, et al. Proceedings of the Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL 281s Abstract #LBA5529